Use of oral contraceptives and risk of breast cancer in BRCA1/2 mutation carriers
M.A. Rookus, DE Goldgar, Nadine Andrieu(Inserm), DF Easton, Richard M. Brohet(The Netherlands Cancer Institute), Jenny Chang‐Claude(Universität Hamburg), Niklas Loman(Lund University), Marilys Corbex(Centre international de recherche sur le cancer)
Cited by 1
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer
|Nature Medicine|2019|1.5k
Large-scale genotyping identifies 41 new loci associated with breast cancer risk
|Nature Genetics|2013|1.1k